Transgenic mouse and cell culture models demonstrate a lack of mechanistic connection between endoplasmic reticulum stress and tau dysfunction.
In vivo aggregation of tau protein is a hallmark of many neurodegenerative disorders, including Alzheimer's disease (AD). Recent evidence has also demonstrated activation of the unfolded protein response (UPR), a cellular response to endoplasmic reticulum (ER) stress, in AD, although the role of the UPR in disease pathogenesis is not known. Here, three model systems were used to determine whether a direct mechanistic link could be demonstrated between tau aggregation and the UPR. The first model system used was SH-SY5Y cells, a neuronal cultured cell line that endogenously expresses tau. In this system, the UPR was activated using chemical stressors, tunicamycin and thapsigargin, but no changes in tau expression levels, solubility, or phosphorylation were observed. In the second model system, wild-type 4R tau and P301L tau, a variant with increased aggregation propensity, were heterologously overexpressed in HEK 293 cells. This overexpression did not activate the UPR. The last model system examined here was the PS19 transgenic mouse model. Although PS19 mice, which express the P301S variant of tau, display severe neurodegeneration and formation of tau aggregates, brain tissue samples did not show any activation of the UPR. Taken together, the results from these three model systems suggest that a direct mechanistic link does not exist between tau aggregation and the UPR.
Department of Chemical Engineering, University of Delaware, Newark, DE 19716, USA.
M L
ML
Spatara
A S
AS
Robinson
D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D002478:Cells, Cultured; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000633:toxicity; D014644:Genetic Variation; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010766:Phosphorylation; D012995:Solubility; D013312:Stress, Physiological / Q000187:drug effects / Q000502:physiology*; D019284:Thapsigargin / Q000633:toxicity; D014415:Tunicamycin / Q000633:toxicity; D056811:Unfolded Protein Response / Q000187:drug effects / Q000502:physiology*; D016875:tau Proteins / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; C054369:MAPT protein, human; D016875:tau Proteins; D014415:Tunicamycin; D019284:Thapsigargin